More detailed compositional analysis and documentation of crop material used in animal feeding studies used in safety assessments may also be warranted. The results presented here emphasize the need to understand natural variation in providing biological context to pair-wise differences in any recorded toxicological or nutritional profiles during comparisons of animals fed diets containing GM plant material (often grain) with diets containing the comparator conventional plant material. Reference crops are typically used in feeding studies in regulatory safety assessments as a means to encompass compositional variation in the test crop, yet are often excluded in other published reports. The unfortunate consequences of omitting references and eschewing careful compositional analyses in feeding studies have been documented in a nonpeer reviewed Feature article in this journal 13 .
The economic and environmental impacts of the global adoption of GM crops over the past decade have been reviewed 6, 14, 15 . GM crops are credited with increased yields, decreased pesticide and fuel use and, particularly in the case of herbicide-tolerant crops, with facilitating conservation tillage practices. It can be concluded that these derived benefits have been accompanied by consistent compositional quality and that compositional quality implies a very broad range of compositions and endogenous levels of single constituents. The findings from the analysis reported here may prove relevant to research strategies and public policy evaluations of the safety and nutritional value of GM and conventional crops. versus 234 p.p.m.) in A5547 relative to that of Monsoy 8329. These differences were substantially greater in magnitude than differences observed in test and control comparisons (Supplementary Table 21 ). All multivariate analyses presented in Supplementary Figures 12-24 were consistent with this conclusion that differences in growing location and/or genetic background contributed more to compositional variation than transgene insertion.
This analysis reviewed compositional data, generated under OECD guidelines, from a total of seven different GM crop varieties grown over a wide geographic area and a total of eleven growing seasons. It presents the most comprehensive compilation of GM crop composition data that we are aware of (Supplementary Table 20 ) and reveals that the compositional data for agronomically equivalent transgenic and conventional crops fall indistinguishably within the same space. It can be concluded that incorporation of biotech-derived agronomic traits has had little impact on natural variation in crop composition and that most compositional variation is attributable to growing region, agronomic practices and genetic background. This also supports the hypothesis that the compositional quality, and by extrapolation, the nutritional quality of GM crops with enhanced agronomic traits is consistently maintained.
Several considerations follow from our observations. For example, at least one study 8 has recommended that compositional assessments of new crop varieties, and not the breeding technologies adopted in their development, serve as the basis for regulatory evaluation. The results presented here imply that if regulatory scrutiny is to be commensurate with the potential for compositional deviation, there is no reason to prioritize crops on the basis of genetic modification via transgenesis over crops genetically modified via conventional breeding, chemical mutagenesis or irradiation. This is consistent with the product-based regulatory principle that "products, substances and tangibles" should be the basis of risk assessments and not the processes involved in creating those products (for a discussion, see refs. 9,10). It is noteworthy that two recent commentaries on the application of transgenic technology presented in Nature Biotechnology have discussed the impact of prioritizing GM breeding strategies in the regulatory approval process as leading to curtailing "agbiotech product quality innovation" 11 and "strangling at birth" forest biotech 12 . we refined (Supplementary Methods and Supplementary Fig. 1 ) and used for different simulations. In particular, we ran two simulation experiments-'simulation I' for Bt cotton and 'simulation II' for conventional cotton-both modeling an expansion in the village cotton area by 1 hectare. Using a village modeling approach taking into account both direct and indirect benefits, our study found that Bt cotton technology generates not only higher income but also more employment, especially for hired female labor 3, 4 . Compared with conventional cotton ( Fig. 1 ; simulation II), Bt cotton ( Fig. 1; simulation  I ) generates additional employment, raising the total wage income by $40 per hectare 4 . The largest increase is for hired females with a gain of 55% from Bt cotton. This translates to about 424 million additional employment opportunities for female earners for the total Bt cotton area in India. Increase in returns to hired female labor is mostly related to higher yields in Bt cotton, due to the additional labor employed for picking the increased production of cotton (harvesting of cotton is primarily a female activity in India).
GM crops and gender issues
For family female labor, additional income from Bt cotton leads to withdrawal of in-house females from farming activities, raising the quality of life of women. Although reduced pesticide applications in Bt cotton is labor saving, the returns to family male labor that largely carry out this activity is higher (Fig. 1) . Even so, some of the saved family male labor involved in scouting and spraying for pests are reallocated to other household economic activities, previously carried out by female family members, increasing the returns to this labor category. Overall, therefore, Bt cotton enhances the quality of life of women through increasing income and reducing 'femanual' work.
Note: Supplementary information is available on the Nature Biotechnology website.
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The authors declare no competing financial interests. On the basis of these issues, we feel that Gressel presents only part of the story and that quality of life for women in developing countries depends not only on the 'femanual' work but also on the incomes they earn. Thus, addressing gender issues in biotech requires rigorous analysis and a comprehensive evaluation beyond that outlined by Gressel. Here we summarize recent research by two of us (A.S. & M.Q.) 3, 4 on the gender effects of insect-resistant Bacillus thuringiensis toxin (Bt) cotton in India, which indicates that this technology generates more employment for females, who happen to earn much more than males.
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Since its commercialization in India in the year 2002, the area in which Bt cotton is cultivated increased to 7.6 million hectares in 2008 (ref. 5) . Several studies show sizable direct benefits of the technology and also indirect benefits from spillovers to other rural markets and sectors [6] [7] [8] , but no studies analyzed the gender aspect of this technology. To analyze the gender implications of Bt cotton adoption, we carried out two household surveys 3, 4 . The first survey was undertaken in one village where we collected comprehensive data on household characteristics and interactions across various markets. The study village, Kanzara, is located in the Akola district of Maharashtra, the state with the largest area under cotton in India. Kanzara can be considered a typical setting for small-holder cotton production in the semi-arid tropics 9 hectares. All farm households cultivate at least some cotton, mostly next to a number of food and fodder crops for subsistence consumption and for sale.
This information was updated using the second survey: panel data from a farm sample survey conducted over a period of 5 years 10 . We used this more representative survey data to further improve the robustness of the results 3, 4 . Based on these two data sources, we developed a social accounting matrix (SAM) for Kanzara, which represents the flows of all economic transactions that take place within the village economy (Supplementary Table 1 and Supplementary Methods). Over the [2003] [2004] . the gross domestic product of the village was about $0.53 million. Village SAMs have been developed and used previously in different contexts [11] [12] [13] . Yet, our SAM is distinct in two respects. First, unlike previous SAMs, which are all based on sample surveys, our SAM builds on a village census. Because a SAM by construction requires both receipts and payments of all transactions, availability of census data reduces the problem of unbalanced markets and thus of biased results. Second, our SAM explicitly considers both Bt cotton and conventional cotton as two different activities, which allows us to evaluate both technologies' distributional impacts.
Even so, the SAM as such is a static representation of the village economy and does not allow statements to be made about income distribution effects of individual activities like Bt cotton. To do this requires a SAM multiplier model, which fair incentives for continued biomedical innovation. BIO spent the past 3 years tirelessly educating members of the House and Senate on the complexity of biologics and the importance of providing a significant period of data exclusivity to allow biotech companies to recover their expenses and provide an adequate return on investment. Without the guarantee of this return on investment, firms such as ours would have great difficulty in raising funds to finance the next-generation innovative therapies.
BIO also has been a leading player in advocating meaningful patent reform legislation that will help promote continued biotechnology innovation and help drive US economic growth. Patents are often the sole assets of many BIO members. As such, strong and predictable patent protection enables the flow of risk capital that is vital to achieving biotechnology's promise. While patent reform legislation continues to wind its way through Congress, BIO has successfully advocated for several key provisions that will strengthen the US patent system and enhance patent quality.
Perhaps as crucial as the issues that BIO's board chooses to advocate for is our approach. BIO has, and will continue to be, policy led. Our engagements with members of Congress are oriented around the key facts about our industry, without regard to party or politics. The industry that BIO represents is based on cutting-edge science, and our efforts are supported by data and facts.
In addition to its advocacy efforts on behalf of companies, BIO hosts industryleading investor and partnering meetings in the United States and around the world to provide emerging companies with investment, licensing and other partnership opportunities.
BIO is committed to be the voice of all biotech companies-whether small, medium or large. Although the difficulty of doing so is not lost on us, the voice of small biotech is both loud and clear-and, we are happy to report, being heard.
